Cost-Effectiveness Analysis of Obinutuzumab Associated to Chlorambucil for the Treatment of Slow-Go Patients with Chronic Lymphocytic Leukemia (CLL) Under the Brazilian Public Healthcare System
Abstract
Authors
R Ho C Rufino J Biondo M Alves